Tabirafusp alfa
Multispecific antibody
Also known as KSI-101
Evidence outlook · registrational
Registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-02.
Company guidance: topline data expected December 2026 (NCT06990399; Kodiak Sciences Inc., 12 Nov 2026). “Phase 3 PEAK Study (KSI-101) – Pivotal Analysis 1 Topline Data Expected December 2026” Source ↗
Company guidance: regulatory filing expected second quarter of 2027 (Kodiak Sciences Inc., 12 Nov 2026). ““Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PEAK NCT06990399 · Macular Edema Secondary to Inflammation Registry: NCT06990399 | 3 | Mean change in BCVA (Week 24) 2027-04 | In progress: results expected 1 Apr 2027 | not yet graded | link ↗ |
View 1 more trial
PINNACLE NCT06996080 · Macular Edema Secondary to Inflammation Registry: NCT06996080 | 3 | Mean change in BCVA (Week 24) 2027-02 | In progress: results expected 1 Feb 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Competitive landscape
Other VEGF + IL-6 drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tabirafusp Alfa: this drug | Phase 3 | Multispecific antibody | VEGF + IL-6 | not yet graded | No reviewed efficacy summary | |
| Tabirafusp Tedromer | Phase 3(overall) | Multispecific antibody | VEGF + IL-6 | Partial signal | NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28). |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tabirafusp alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
February 2027 (1)
What to watch
April 2027 (1)
Company guidance: topline data expected December 2026 (Kodiak Sciences Inc., 12 Nov 2026). “Phase 3 PEAK Study (KSI-101) – Pivotal Analysis 1 Topline Data Expected December 2026” Source ↗